Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alfacell (ACEL) -- Ignore unavailable to you. Want to Upgrade?

To: r. parker griff who wrote (1446)	7/15/1998 10:20:00 AM
From: F. Jay Abella, III	Read Replies (1) \| Respond to of 1533

Sorry to hear about ACEL today. John J, remember what I wrote you during your inquiry about RFS2000? From: Self <jay> To: "Jenco, John" <jjenco@lawson.epri.com> Subject: RE: [Westergaard biomedtech: "F.J. Abella" <jay@westergaard.com> Date sent: Tue, 19 May 1998 12:27:16 John: Somehow I knew this question was going to come up. With regard to ACEL's Onconase for pancreatic cancer, results were generated in combination with other chemos while RFS2000 was given orally as monotherapy. Oddly, ACEL's 10-K does not mention any clinical results for Onconase. More discussion of corporate finance and warrants than clinical data is a trouble sign, IMO. FJA Now there is a way to avoid this happening to you again: biomedfinance.com